ClinicalTrials.gg
RecruitingNCT07400458Updated Feb 10, 2026

Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration

An interventional study of Hearticellgram-AMI in Acute Myocardial Infarction, sponsored by Pharmicell Co., Ltd.. Recruiting at 1 site in South Korea. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Pharmicell Co., Ltd. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Mar 2022, registered May 2024).
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Myocardial Infarction with a site in Korea, Republic of — 21 open to participants now, 26 under way, 5 of them phase 3. Myocardial Infarction · Korea, Republic of.

Planned enrollment
57th of 73
100 · median 820
Started
2022
with 4 others
No phase
18 of 99
8 open now
Primary completion
2028-10
later than 15 of 25 live
Registered
91st of 99
by date

Among the 99 studies in Myocardial Infarction with a site in Korea, Republic of, this one is the 57th largest by planned enrollment of the 73 interventional ones that give a count, is one of 5 that started in 2022, is one of 18 with no phase, reaches primary completion later than 15 of the 25 other live ones, and was the 91st registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

21 of the 99 studies in Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Myocardial Infarction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.

Read the detailed description

To evaluate the safety for 60 months after a single dose of Hearticellgram-AMI in patients with Acute Myocardial Infarction.

03

Conditions studied

  • Acute Myocardial Infarction
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Those who had administered Hearticellgram-AMI
  2. Those who voluntarily agreed in writing to participate in this investigation

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Hearticellgram-AMI

    Patients with Acute Myocardial Infarction who had administered Hearticellgram-AMI.

    Biological: Hearticellgram-AMI

Interventions

  • BiologicalHearticellgram-AMI

    Patients who had administered Hearticellgram-AMI.

06

What researchers measure

Primary outcomes

  1. Rate of AESI

    death, neoplasms or malignancies in tissues or organs, Immune response

    Time frame: For 5 years

07

Study locations

1 of 1 sites recruiting
  • KIMHYUNSOO Clinic
    Seoul, Gangnam 06017, South Korea
    Recruiting
    • HYUNSOO KIM · Contact82-2-511-1101
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Oct 2028, 79 months after the start.

Of 33 industry-sponsored interventional studies with no phase under Myocardial Infarction, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's planned 79 months is above that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
Feb 10, 2026
StartActual
Mar 3, 2022
Primary completionEst.
Oct 12, 2028
CompletionEst.
Sep 30, 2032
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07400458
Lead sponsor
Pharmicell Co., Ltd.
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Mar 3, 2022
Primary completion
Oct 12, 2028 (estimated)
Completion
Sep 30, 2032 (estimated)
Last update
Feb 10, 2026

Study contacts

DAEUN JUNG
Contact
daeun4100@pharmicell.com
82-2-3496-0134

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion